Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's First "Bad Ad" Citation Goes To Hill Dermaceuticals

This article was originally published in The Pink Sheet Daily

Executive Summary

Program aimed at encouraging doctors to report promotions they find worrisome generates a DDMAC warning letter about a Web site for Derma-Smoothe.

You may also be interested in...



FDA Enforcement Letters On Rx Drug Promotions Plummet In 2013

OPDP Director Tom Abrams cautions against reading into the “snapshot.”

Hill Dermaceuticals Rewrites The Lab Books, So FDA Throws The Book At The Firm

A district court issued a consent decree against Hill, its president and quality assurance manager; government alleges the company repeatedly failed to correct violations cited by FDA since 2004.

Hill Dermaceuticals Rewrites The Lab Books, So FDA Throws The Book At The Firm

A district court issued a consent decree against Hill, its president and quality assurance manager; government alleges the company repeatedly failed to correct violations cited by FDA since 2004.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071609

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel